在沙特阿拉伯,与结肠直肠癌相关的资源利用和医疗保健成本
Bander Balkhi1, Ahmed Alghamdi1, Saeed Alqahtani1
1Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
概括
沙特阿拉伯的结直肠癌的经济负担很大,在四年内耗资1900万美元. 药物和手术费用是主要的驱动因素,影响沙特医疗保健预算.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 公共卫生 公共卫生
背景情况:
- 在沙特阿拉伯,结肠直肠癌的发病率正在上升.
- 有限的数据存在于结直肠癌的经济负担,特别是在沙特阿拉伯.
- 虽然先进的癌症治疗是有益的,但存在相当大的经济挑战.
研究的目的:
- 为了估计沙特阿拉伯结肠直肠癌的经济负担.
- 确定与结直肠癌治疗相关的主要成本驱动因素.
主要方法:
- 进行了一项回顾性,单一中心的疾病成本研究.
- 分析了2017年1月至2020年12月期间结直肠癌患者的数据.
- 使用微成本,自下而上的方法来确定医疗保健资源利用率和直接医疗成本.
主要成果:
- 这项研究包括326名结直肠癌患者.
- 总的直接医疗费用为1900万美元,每名患者的平均年度费用为58384美元.
- 药物费用 (45%) 和手术费用 (27%) 是整体支出的主要贡献者.
结论:
- 结肠直肠癌给沙特医疗保健系统带来了巨大的经济负担.
- 预计的人口增长,人口老龄化和昂贵治疗的可用性可能会增加未来的成本.
- 这些发现对于政策制定者解决沙特阿拉伯结直肠癌的经济挑战至关重要.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
293
06:28E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
8.4K
相关概念视频
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356
Hazard Ratio
130
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
130
